Business Wire

NEXO

23.9.2021 15:32:09 CEST | Business Wire | Press release

Share
Nexo Passes Real-Time Reserves Audit Conducted by Armanino

Nexo, the leading institution for digital assets, today announced that Armanino LLP – a PCAOB-certified auditor and one of the 25 largest public accounting firms in the U.S. – now provides a real-time audit of Nexo’s assets, thus offering unparalleled visibility into Nexo’s finances and showing that the company’s assets exceed its liabilities at all times.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005619/en/

Armanino’s real-time attestation of Nexo’s assets and customer obligations brings a level of customer security unprecedented in the crypto lending space. The independent audit also represents a significant milestone in Nexo’s transparency and compliance journey and marks only the beginning of a routine Proof of Reserves program. The next step will allow each client to verify for themselves that their particular assets are included in the daily reports.

The third-party audit, coupled with the company’s proactive stance on regulation and years of following the traditional licensing procedures around the globe, is testimony to Nexo's resolve and ability to adapt to changing circumstances and to best protect and serve its clients’ interests. This positions the company ahead of the curve as it gears up to join the prime brokerage race, launch its asset management division, and welcome institutional demand as one of the most secure, progressive, and compliant businesses.

Armanino’s TrustExplorer© attest platform will provide enhanced visibility into Nexo’s underlying assets of its Borrow and Earn Crypto Interest products through viewable and downloadable attest reports that are generated and updated daily.

You can view the real-time audit on the Nexo attest report page:

https://real-time-attest.trustexplorer.io/nexo

“In the long run, the companies that provide their customers the necessary transparency, security and peace of mind, will win. Amidst increased regulatory interest in the cryptocurrency industry, we at Nexo are setting the bar so as to prove to our clients and investors that the assets entrusted to us are indeed in good hands, a testament to which is the independent audit by Armanino. We challenge other lenders and crypto leaders to follow our lead,” commented Antoni Trenchev, Co-founder and Managing Partner of Nexo.

"As innovative companies like Nexo create the next generation of financial products and enable customer-first offerings, Armanino knows that attest tools must keep up with the pace of innovation,” said Noah Buxton, Managing Director and Practice Leader of Armanino’s Blockchain & Digital Assets Practice. “After a lot of mutual hard work and breaking of new ground, we are excited to unveil another world-first for the crypto and digital assets market. Meaningful transparency, on-demand, and unpermissioned. This is the new paradigm.”

For businesses in the financial sector, customer trust is a foundational block and showing reserves are fully backed goes a long way in further enhancing that trust. With the latest in the #NexoTransparency campaign, Nexo is pleased to be one of the first crypto lenders to tap the innate auditability of cryptocurrencies and to set an example for others in the crypto industry to follow.

About Nexo

Nexo is the world's leading regulated digital assets institution. The company’s mission is to maximize the value and utility of cryptocurrencies by offering tax-efficient Instant Crypto Credit Lines™, a high-yield Earn Crypto Interest suite, an instant Exchange service, and sophisticated trading and OTC capabilities, while providing the top-tier custodial insurance and military-grade security of the Nexo Wallet. Nexo has processed $50+ billion for 2,000,000+ users across more than 200 jurisdictions.

Official website: https://nexo.io

About Armanino LLP

Armanino LLP (www.armaninollp.com ) is one of the 25 largest independent accounting and business consulting firms in the nation. Armanino provides an integrated set of audit, tax, business management, consulting and technology solutions to companies in the U.S. and globally. The firm helps clients adapt and change in every stage of business, from startup through rapid growth to the sale of a company. Armanino emphasizes smart technology, leading a cloud revolution of financial, operational, sales and compliance tools that are transforming the way companies do business. The firm extends its global services to more than 100 countries through its membership in Moore Global, one of the world's major accounting and consulting membership organizations. In addition to its core consulting and accounting practices, Armanino operates its division, AMF Media Group (www.amfmediagroup.com ), a media and communications services agency. Its affiliate, Intersect Capital (www.intersectcapitalllc.com ) is an independent financial planning, wealth and lifestyle management firm.

More information on Real-Time Attest:

https://www.armaninollp.com/software/trustexplorer/real-time-attest/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release

Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai

Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release

Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye